<DOC>
	<DOCNO>NCT01519128</DOCNO>
	<brief_summary>The purpose study investigate effect steady-state ( constant concentration medication blood ) TMC278 single dose pharmacokinetics ( body medication ) digoxin .</brief_summary>
	<brief_title>A Study Investigate Effect Steady-State TMC278 Pharmacokinetics Single Dose Digoxin</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , randomize ( study medication assign chance ) , crossover ( method use switch patient one treatment arm another clinical study ) study investigate effect steady-state TMC278 single dose pharmacokinetics digoxin . The study consist 3 phase , include screen phase , treatment phase , follow-up phase . After screen phase , participant randomize one 2 treatment sequence consist Treatments A B , ie , Sequence AB ( 11 participant ) , Sequence BA ( 11 participant ) . Treatment phase include , Treatment A : digoxin 0.5 mg ( single oral dose ) , Treatment B : TMC278 25 mg daily digoxin 0.5 mg ( single oral dose ) . The 2 consecutive sequence separate washout period ( period receive treatment ) least 14 day . Safety evaluation adverse event , clinical laboratory test , electrocardiogram , cardiac telemetry , vital sign , physical examination , alcohol breath test , specific toxicity monitor throughout study.The study duration treatment phase least 26 day .</detailed_description>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Women must postmenopausal least 2 year , surgically sterile Men must agree use highly effective method birth control donate sperm study 3 month receive last dose study medication A positive HIV1 HIV2 test screen Hepatitis A , B C infection screen History clinically relevant heart rhythm disturbance History idiopathic hypertrophic subaortic stenosis , atrioventricular block , ventricular tachycardia/ventricular fibrillation family history sudden cardiac death</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>TMC278</keyword>
	<keyword>TMC278IFD1001</keyword>
	<keyword>Human immunodeficiency virus - type 1</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Digoxin</keyword>
</DOC>